Hormone-Drug Combo May Help Bone Density
Posted on: Tuesday, 20 May 2003, 06:00 CDT
By LINDSEY TANNER
CHICAGO (AP) -- Hormone supplements plus a bone-building drug work better at increasing bone density than either treatment alone in older women, a study suggests.
The study involved 373 women ages 65 to 90 who had either thinning bones or full-blown osteoporosis and took one of four treatments for three years: hormones combined with alendronate, sold as Fosamax; hormones alone; Fosamax alone; or dummy pills.
Last summer, a study was published linking hormone supplements with heart attacks, strokes and breast cancer.
But the incidence of those problems was extremely low in the new study, said lead author Dr. Susan Greenspan, professor of medicine at the University of Pittsburgh. The hormones-Fosamax treatment "was safe and well-tolerated," said Greenspan, who has worked as a consultant for Fosamax maker Merck Research Laboratories.
Greenspan said her study suggests the hormones-Fosamax treatment may be an option for older women who face a severe risk of osteoporosis and bone fractures.
The findings appear in Wednesday's Journal of the American Medical Association.
The hormone study released last summer, the Women's Health Initiative, led many doctors to recommend against using hormone supplements for any reason other than relief of short-term menopause symptoms. And a WHI researcher, Jennifer Hays, said the new findings are not convincing enough to recommend hormones for osteoporosis prevention even in older women.
Hays, a Baylor College of Medicine psychologist, said the bone-enhancing benefits from estrogen come only after long-term use - which also carries the highest risk of breast cancer or heart disease.
The hormones used in the Fosamax study contained estrogen alone or estrogen-progestin.
After three years, hip bone density had increased nearly 6 percent in women on hormones plus Fosamax, 4 percent in those on Fosamax, and 3 percent in the hormones-only group. Increases also were seen in spinal bone density.
Higher bone density is usually associated with fewer fractures.
-----
On the Net:
Journal of the American Medical Association
More science, space, and technology from RedNova
Copyright © 2003 The Associated Press. All rights reserved. The information contained in the AP News report may not be published, broadcast, rewritten or redistributed without the prior written authority of The Associated Press.
Related Articles
- Denosumab Osteoporosis Trial Finds Patients Transitioned From Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density Versus Those Continuing on Alendronate
- Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial Versus Weekly Alendronate (FOSAMAX(R))
- Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study
- Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison With Weekly Alendronate (FOSAMAX(R))
- New Study Shows Once-Monthly Boniva(R) is As Clinically Effective As Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
- Hormone therapy less risky for younger women-study
- Menopausal Hormone Therapies: Their Effect on Mammographic Density and Breast Cancer Risk
- Effects of Low-Dose Hormone Therapy on Menopausal Symptoms, Bone Mineral Density, Endometrium, and the Cardiovascular System: a Review of Randomized Clinical Trials
- New Data Show Most Postmenopausal Women in Study Who Initiated Therapy With Wyeth's Low Dose Hormone Therapies Achieved Increased Bone Mineral Density
- Lipid-Modifying Effects of Rosuvastatin in Postmenopausal Women With Hypercholesterolemia Who Are Receiving Hormone Replacement Therapy*
 |
 |
User Comments (0)
RSS Feeds